Project Grant HT94252311024
Award Date
9/15/23
Completion Date
9/14/26
Dollars Obligated
$520K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $523,266 project grant to the University of California Irvine. The 3-year grant, awarded on Sep 15, 2023, will support intravital imaging research on melanoma tumors to improve understanding of the mechanisms of action and patient surveillance for checkpoint blockade immunotherapy. The project aims to leverage UC Irvine's research capabilities and specialized facilities in biomedical...
The University of California Irvine (UC Irvine) was awarded a $513,084.00 Project Grant by the Defense Health Agency under the Department of Defense's Military Medical Research and Development program (CFDA 12.420). The grant, titled "Intravital Imaging of Melanoma Tumors for Mechanism Discovery and Patient Surveillance After Checkpoint Blockade", will fund research to investigate innovative imaging techniques for studying melanoma tumors and monitoring patient response to...
The federal Project Grant award of $1,008,313 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. This award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award was granted to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution, to conduct research on melanoma....
This federal Project Grant award of $1,041,595.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Regents of the University of California, San Francisco (UCSF) on September 1, 2024. The award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, this 3-year Melanoma Research Program Team Science Award will fund innovative and...
The Defense Health Agency awarded Duke University a $804,999 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support research on "DETECTING MISSED METASTASES FROM NOMINALLY EARLY-STAGE MELANOMAS WITH PUMP-PROBE MICROSCOPY". The award runs from September 1, 2023 to August 31, 2026. The Project Grant enables Duke's research to transform health care for Service Members and the American public through innovative and impactful biomedical research...
This $646,252 Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) supports research to uncover cell intrinsic and extrinsic factors governing melanoma dormancy at single-cell resolution. The primary awardee, Trustees of Boston University, will conduct this advanced biomedical research. The University of Virginia will provide academic and technical resources, including experiments generating and validating...
This Project Grant award of $172,355 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of Connecticut Health Center to investigate spatial transcriptomic and proteomic shifts in tumor-infiltrating immunocytes, with the goal of enhancing melanoma therapeutics. The research aims to chart a path for improved treatment of melanoma by mapping changes in gene expression and protein levels within immune cells...
This Project Grant award from the Defense Health Agency, through the Military Medical Research and Development program (CFDA 12.420), provides $514,335 to Yale University to optimize adoptive cellular immunotherapy for rare melanomas. The award began on September 1, 2023 and is scheduled for completion on August 31, 2026. The research aims to transform health care for service members and the American public through innovative and impactful medical solutions, with a focus on developing treatments...
This Project Grant award in the amount of $590,625.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports a pilot study at the University of California, Los Angeles (UCLA) to investigate dual immunotherapy (PD1/CD73) in combination with chemotherapy for patients with pancreatic adenocarcinoma, with a focus on understanding the immune mechanisms of resistance. The award period runs from...
This Project Grant award of $590,625.00 from the U.S. Department of Defense's Military Medical Research and Development (CFDA 12.420) program supports a pilot study at the University of California, Los Angeles (UCLA) to investigate the use of dual immunotherapy (PD1/CD73) in combination with chemotherapy for treating patients with pancreatic adenocarcinoma. The study aims to elucidate the immune mechanisms of resistance to this treatment approach. The award has a performance period from...